Green-Med Diet and the Brain; COVID Smell-Loss Gene; Unfamiliar Voices During Sleep

A high-polyphenol Mediterranean (Green-Med) diet was linked to slower age-related brain atrophy, MRI data showed. (American Journal of Clinical Nutrition)

People with higher levels of amyloid beta-38 in their cerebrospinal fluid declined less on the Mini-Mental State Exam. (Neurology)

A genetic locus near UGT2A1 and UGT2A2 was associated with COVID-19-related loss of smell or taste. (Nature Genetics)

Oral dissolving buprenorphine upped the risk of severe dental problems, the FDA warned.

The human brain paid attention to unfamiliar voices during sleep, polysomnography studies revealed. (Journal of Neuroscience)

Jennifer Aniston once had sleep troubles; now she is helping Idorsia Pharmaceuticals launch a campaign to help people learn about insomnia, the company said.

The case of a 67-year-old man with motor neuron disease who enacted dreams and exhibited odd behavior during sleep was featured in the New England Journal of Medicine.

The annual price of aducanumab (Aduhelm) should range from $2,950 to $8,360 to meet commonly used cost-effectiveness thresholds, according to an ICER analysis reviewed and published in Neurology.

Patient groups, including the Alzheimer’s Association and Us Against Alzheimer’s, are taking aim at CMS over its proposed aducanumab coverage decision. (Politico)

Cardiovascular comorbidities exacerbated pre-existing amyloid plaques in mouse models of Alzheimer’s disease. (eLife)

The FDA placed a clinical hold on studies of DNL919, an Alzheimer’s antibody transport vehicle drug engineered to cross the blood-brain barrier, Denali Therapeutics said.